Voriconazole-Induced Phototoxicity Masquerading as Chronic Graft-versus-Host Disease of the Skin in Allogeneic Hematopoietic Cell Transplant Recipients

被引：29

作者：

Patel, Asha R.

Turner, Maria L.

Baird, Kristin ^{[2
]}

Gea-Banacloche, Juan ^{[3
]}

Mitchell, Sandra ^{[4
]}

Pavletic, Steven Z. ^{[3
]}

Wise, Barbara ^{[2
]}

Cowen, Edward W. ^{[1
]}

机构：

[1] NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA

[2] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA

[3] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, Bethesda, MD 20892 USA

[4] NIH, Ctr Clin, Bethesda, MD 20892 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2009年 / 15卷 / 03期

关键词：

Graft-versus-host disease; Voriconazole; Phototoxicity; Fungal infection; CONSENSUS DEVELOPMENT PROJECT; WORKING GROUP-REPORT; INVASIVE ASPERGILLOSIS; ANTIFUNGAL AGENTS; CLINICAL-TRIALS; PSEUDOPORPHYRIA; CHILDREN; THERAPY; DRUG; PHOTOSENSITIVITY;

D O I：

10.1016/j.bbmt.2008.12.491

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Systemic fungal infections pose a significant risk to patients following allogeneic hematopoietic cell transplantation (alloHCT). Voriconazole (Vfend (R), Pfizer) is an oral second-generation triazole antifungal agent that offers a broad spectrum of coverage against fungal species and is frequently utilized in the post-HCT setting. Herein, we describe 5 patients who were initially believed to be experiencing a flare of cutaneous chronic graft-versus-host disease (cGVHD), but who were actually exhibiting phototoxicity caused by voriconazole. A high index of suspicion for this adverse reaction in the post-alloHCT setting will prevent misdiagnosis and avoid inappropriate therapy for cGVHD.

引用

页码：370 / 376

页数：7

共 36 条

[1] Voriconazole photosensitivity: 7 cases. [J].

Auffret, N. ;

Janssen, F. ;

Chevalier, P. ;

Guillemain, R. ;

Amrein, C. ;

Le Beller, C. .

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2006, 133 (04) :330-332

[2] Newer systemic antifungal agents - Pharmacokinetics, safety and efficacy [J].

Boucher, HW ;

Groll, AH ;

Chiou, CC ;

Walsh, TJ .

DRUGS, 2004, 64 (18) :1997-2020

[3] Successful treatment of coccidioidal meningitis with voriconazole [J].

Cortez, KJ ;

Walsh, TJ ;

Bennett, JE .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1619-1622

[4] Ancillary therapy and supportive care of chronic graft-versus-host disease:: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease:: V.: Ancillary Therapy and Supportive Care Working Group report [J].

Couriel, D ;

Carpenter, PA ;

Cutler, C ;

Bolaños-Meade, J ;

Treister, NS ;

Gea-Banacloche, J ;

Shaughnessy, P ;

Hymes, S ;

Kim, S ;

Wayne, AS ;

Chien, JW ;

Neumann, J ;

Mitchell, S ;

Syrjala, K ;

Moravec, CK ;

Abramovitz, L ;

Liebermann, J ;

Berger, A ;

Gerber, L ;

Schubert, M ;

Filipovich, AH ;

Weisdorf, D ;

Schubert, MM ;

Shulman, H ;

Schultz, K ;

Mittelman, B ;

Pavletic, S ;

Vogelsang, GB ;

Martin, PJ ;

Lee, SJ ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (04) :375-396

[5] Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole [J].

Denning, DW ;

Griffiths, CEM .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (08) :648-653

[6] Pseudoporphyria as a result of voriconazole use: a case report [J].

Dolan, CK ;

Hall, MA ;

Blazes, DL ;

Norwood, CW .

INTERNATIONAL JOURNAL OF DERMATOLOGY, 2004, 43 (10) :768-771

[7] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report [J].

Filipovich, AH ;

Weisdorf, D ;

Pavletic, S ;

Socie, G ;

Wingard, JR ;

Lee, SJ ;

Martin, P ;

Chien, J ;

Przepiorka, D ;

Couriel, D ;

Cowen, EW ;

Dinndorf, P ;

Farrell, A ;

Hartzman, R ;

Henslee-Downey, J ;

Jacobsohn, D ;

McDonald, G ;

Mittleman, B ;

Rizzo, JD ;

Robinson, M ;

Schubert, M ;

Schultz, K ;

Shulman, H ;

Turner, M ;

Vogelsang, G ;

Flowers, MED .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) :945-956

[8] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[9]

Hilliard Tom, 2005, J Cyst Fibros, V4, P215, DOI 10.1016/j.jcf.2005.05.019

[10]

Hood AF, 2000, PATHOLOGY SKIN, P204

← 1 2 3 4 →